Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.56 |
| ▸ | PARP2 | Q9UGN5 | 10/20 | 0.54 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077800 | 0.92 | PARP1 (0.54) | PARP1KCNH2PARP2 | |
| SCHEMBL8065074 | 0.83 | PARP1 (0.65) | PARP1KCNH2PARP2DAO | |
| SCHEMBL8071284 | 0.81 | PARP1 (0.71) | PARP1KCNH2PARP2 | |
| SCHEMBL8070885 | 0.81 | PARP1 (0.63) | PARP1KCNH2PARP2DAO | |
| SCHEMBL8077397 | 0.80 | PARP1 (0.60) | PARP1KCNH2PARP2 | |
| Hydrochloric Acid SCHEMBL31571003 | 0.80 | PARP1 (0.62) | PARP1KCNH2PARP2DAO | |
| SCHEMBL8074912 | 0.79 | PARP1 (0.56) | PARP1KCNH2PARP2 | |
| SCHEMBL31570999 | 0.79 | PARP1 (0.58) | PARP1KCNH2PARP2DAO | |
| SCHEMBL8075821 | 0.78 | PARP1 (0.68) | PARP1KCNH2PARP2 | |
| SCHEMBL8076677 | 0.78 | PARP1 (0.55) | PARP1KCNH2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-8404713-B2 | Quinolinone derivatives as PARP inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-26 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-02 | — | — | US | disclosed |
| WO-2009053373-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222348-A1 | QUINOLINONE DERIVATIVES AS PARP INHIBITORS | PARP1, PARP2, PARP11 | PARP1 1/4885KCNH2 2542/4885PARP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.